A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20121-20131

  Yu, Jing ^a   Qiu, Shaowei ^a   Ge, Qiufu ^b   Wang, Ying ^a   Wei, Hui ^a   Guo, Dianwu ^b   Chen, Shuying ^a   Liu, Shuang ^a   Li, Shouyun ^a   Xing, Haiyan ^a   Rao, Qing ^a   Wang, Jianxiang ^a   Wang, Min ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b Hangzhou Huadong Medicine Group Biotechnology Institute Co Ltd   (China)

Author keywords

Alkylating agent; Apoptosis; Histone deacetylase inhibitor; Hybrid; Leukemia

Indexed keywords

ANTILEUKEMIC AGENT; BENDAMUSTINE; CASPASE 3; CELL DNA; DOUBLE STRANDED DNA; HISTONE DEACETYLASE; HISTONE H2AX; HISTONE H3; HYDROXAMIC ACID; NL 101; PLACEBO; PROTEIN BCL XL; UNCLASSIFIED DRUG; VORINOSTAT; ALKYLATING AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; KASUMI 1 CELL LINE; LEUKEMIA CELL; LEUKEMIA CELL LINE; MOUSE; NB4 CELL LINE; NONHUMAN; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SURVIVAL TIME; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BENDAMUSTINE HYDROCHLORIDE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE;

EID: 84940210948     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4041     Document Type: Article

References (38)

1. Buchwald M, Kramer OH and Heinzel T. HDACi-targets beyond chromatin. Cancer Lett. 2009; 280:160-167.
2. Bolden JE, Peart MJ and Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5:769-784.
3. Redner RL, Wang J and Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 1999; 94:417-428.
4. Minucci S, Nervi C, Lo Coco F and Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 2001; 20:3110-3115.
5. Minucci S and Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6:38-51.
6. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T and Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999; 96:4592-4597.
7. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA and Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000; 60:5165-5170.
8. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P and Kelly WK. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006; 24:166-173.
9. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW and Berenson JR. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res. 2011; 35:373-379.
10. Lee CK, Wang S, Huang X, Ryder J and Liu B. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett. 2010; 296:233-240.
11. Ai T, Cui H and Chen L. Multi-targeted histone deacetylase inhibitors in cancer therapy. Curr Med Chem. 2012; 19:475-487.
12. Cai B, Lyu H, Huang J, Wang S, Lee CK, Gao C and Liu B. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Lett. 2013; 335:343-350.
13. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH and Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010; 116:106-114.
14. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S and Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011; 117:2807-2812.
15. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Bottcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Buhler A, Winkler D, Kneba M, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29:3559-3566.
16. Musto P, Fraticelli VL, Mansueto G, Madonna E, Nozza A, Andriani A, Mussetti A, Ballanti S, Bongarzoni V, Baraldi A, Patriarca F, Vincelli D, Falcone A, Derudas D, Califano C, Zambello R, et al. Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. Leuk Lymphoma. 2015:1-4.
17. Rummel MJ and Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. Semin Hematol. 2011; 48 Suppl 1:S24-36.
18. Bartek J, Lukas C and Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol. 2004; 5:792-804.
19. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003; 63:7291-7300.
20. Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA and Ross DD. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res. 2009; 15:1698-1707.
21. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C and Meyn RE. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005; 11:4912-4922.
22. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S and Chen CY. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res. 2007; 67:5318-5327.
23. Cheson BD and Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009; 27:1492-1501.
24. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G and Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14:309-317.
25. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA and Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996; 93:5705-5708.
26. Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y, Xiong SM, Mi JQ, Chen Z, Ren R and Chen SJ. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2011; 108:2450-2455.
27. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989; 81:1088-1092.
28. Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D and Marcucci G. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther. 2007; 321:953-960.
29. Leoni LM and Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol. 2011; 48 Suppl 1:S12-23.
30. Garnock-Jones KP. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs. 2010; 70:1703-1718.
31. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S and Pommier Y. GammaH2AX and cancer. Nat Rev Cancer. 2008; 8:957-967.
32. van Attikum H and Gasser SM. The histone code at DNA breaks: a guide to repair? Nat Rev Mol Cell Biol. 2005; 6:757-765.
33. Ewald B, Sampath D and Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther. 2007; 6:1239-1248.
34. Krishna S, Low IC and Pervaiz S. Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2. Biochem J. 2011; 435:545-551.
35. Lopez H, Zhang L, George NM, Liu X, Pang X, Evans JJ, Targy NM and Luo X. Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage. J Biol Chem. 2010; 285:15016-15026.
36. Zhang XD, Gillespie SK, Borrow JM and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 2004; 3:425-435.
37. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55.
38. Xiang Z, Kreisel F, Cain J, Colson A and Tomasson MH. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol. 2007; 27:267-282.